NCT03652077: A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: If patient does not have TNBC, they must have a solid malignancy known to be microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient
Exclusions: Patients with known active central nervous system metastases and/or carcinomatous meningitis; Patients who received prior treatment with an anti-TIM-3 antibody
https://ClinicalTrials.gov/show/NCT03652077

Comments are closed.

Up ↑